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Abstract
Background: One of the hallmarks of rheumatoid arthritis (RA) is hyperplasia and inflammation of the synovial tissue being
characterized by in situ occurrence of highly differentiated leukocytes. Fms-like tyrosine kinase 3 (Flt3) has a crucial role in
hematopoiesis, regulation of cell proliferation, differentiation and apoptosis. Typically, Flt3 is expressed on early myeloid
and lymphoid progenitors and is activated by its soluble ligand (Flt3-L). The highly differentiated cellular pattern in the
synovium of the RA patients made us hypothesize that Flt3-L, with its ability to induce proliferation and differentiation,
could be of importance in induction and/or progression of arthritis.
Methodology/Principal Findings: To investigate occurrence of Flt3-L in RA we have measured its levels in matched serum and
synovial fluid samples from 130 patients and 107 controls. To analyse the pro-inflammatory role of Flt3-L, we continuously
overexpressed this protein locally in healthy mouse joints using homologous B-cell line transfected with Flt3-L gene.
Additionally, recombinant Flt3-L was instillated intra-articularly in combination with peptidoglycans, a Toll Like Receptor 2-
ligand with stong arthritogenic properties. Our results show significantly higher levels of Flt3-L in the synovial fluid as compared
to serum levels in RA subjects (p= 0.0001). In addition, RA synovial fluid levels of Flt-3-L were significantly higher than these
obtained from synovial fluids originating from non-inflammatory joint diseases (p=0.022). Intra-articular administration of B-cell
line transfected with Flt3-L gene resulted in highly erosive arthritis while inoculation of the same B-cell line without
hyperexpression of Flt3-L did not induce erosivity and only in a minority of cases caused synovial proliferation! Flt3-ligand
potentiated peptidoglycan induced arthritis as compared to mice injected with peptidoglycan alone (p,0.05).
Conclusions/Significance: Our findings indicate that Flt3-L is strongly expressed at the site of inflammation in human RA. It
exerts both pro-inflammatory and tissue destructive properties once in the joint cavity. Owing to these properties,
treatment attempts to neutralize this molecule should be considered in RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory, autoim-
mune joint disease which prognosis has improved over the last
decade owing to better pharmacological treatment. However there
is only a scarce knowledge regarding pathogenesis of RA. RA gives
rise to chronic inflammation and hyperplasia in the joint
synovium, development of pannus, and invasion of leukocytes
followed by destruction of local articular components such as
cartilage and bone. The synovium is normally only a sparsely
cellular structure containing adipocytes and scattered blood vessels
but in RA the synovium is rich in cells showing a high degree of
differentiation, with occurrence of CD4+ T-cells, B-cells, macro-
phages and dendritic cells. Hyperplasia of the synovium results
from a marked increase of macrophage-like and fibroblast-like
synoviocytes [1]. The reason for this markedly changed phenotype
of joint during inflammation is presently unknown.
The Fms-like tyrosine kinase 3 (Flt3) is a membrane bound
tyrosine kinase receptor which has a crucial role in hematopoiesis,
regulating cellular differentiation, proliferation and apoptosis.
Physiologically, it is mainly expressed on early myeloid and lymphoid
progenitors [2] but few studies reported monocyte and granulocyte
expression of Flt3 on mRNA and protein levels [3,4]. The activation
of Flt3-mediated signalling is achieved by interaction between Flt3
and its ligand (Flt3-L) leading to dimerization and phosphorylation
and resulting in differentiation and proliferation of hematopoietic
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3633
stem cells, both of myeloid [5] and lymphoid origin [6]. Flt3-L also
gives rise to differentiation and clonal expansion of human dendritic
cells[7]. Human Flt3-L is a type 1 transmembranous protein
consisting of 235 amino acids. The dominating isoform is the full-
length transmembrane isoform but there are also soluble forms
which consist of different sizes of the extracellular domain. All
isoforms are biologically active. In contrast to the Flt3 receptor, the
Flt3-L is expressed in most human tissues (spleen, thymus, bone
marrow, prostate, kidney, and intestine) but the highest levels are
seen in peripheral blood leukocytes. Serum levels of Flt3-L are low in
healthy individuals but markedly elevated levels are seen in patients
with secondary leukopenia[8].
Flt3-L and its receptor have never been studied in the setting of
arthritis. The typical cellular pattern in the synovium of the RA-
joint with its abundance of highly differentiated cells implies the
possibility that Flt3-L, with its ability to induce differentiation and
proliferation, could be of pathogenic importance. To investigate
the possible role of Flt3-L in RA we have measured the levels of
Flt3-L in serum and synovial fluid of patients and of healthy
controls. Furthermore, we wanted to ascertain in vivo role of
increased Flt3-L levels in the joint by transplanting Flt3-L
secreting cells into healthy mouse joints. Our results show that
Flt3-L induces erosive arthritis in mice and that the levels of Flt3-L
are significantly elevated in the inflamed joints of RA patients.
Materials and Methods
Flt3-L levels in synovial fluids and sera of RA patients
Paired serum (S) and synovial fluid (SF) samples were collected
from 130 RA patients who attended the rheumatology clinics at
Sahlgrenska University Hospital, Go¨teborg for acute joint effusion.
RA was diagnosed according to the American College of
Rheumatology criteria [9]. The patients consisted of 90 females
(mean age 61, age range 24–87, mean disease duration 10 years
(0–41 years)) and 40 males (mean age 59, age range 25–84, mean
disease duration 9 years (0–39 years)). We considered the presence
of rheumatoid factor (RF) of any of the major immunoglobulin
isotypes as positive. Seventy-eight (51 female, 27 male) of the
patients were positive for RF and 52 negative.
Recent radiographs of hand and foot skeleton for all the patients
were performed. The presence of bone erosions, defined as the loss of
cortical definition in the joint, was recorded in proximal interpha-
langeal joints, metacarpophalangeal joints, carpus, wrist joints and
metatarsophalangeal joints. The presence of one erosion was
sufficient to fulfil the requirement of an erosive disease. Seventy-
eight (51 female, 27 male) of the patients were erosive and 52 non-
erosive. The pharmacotherapy of RA patients is provided in Table 1.
Blood samples from healthy individuals (n = 70; mean age 52
and age range 18–73; 54 females and 16 males) were used as
controls. In addition, synovial fluids from patients with traumatic
knee joint injuries and osteoarthritis were used as controls (n = 37;
mean age 47 and age range 22–88; 17 females and 20 males).
Synovial fluid samples were obtained by arthrocentesis of knee
joints. Synovial fluid was aspirated aseptically and transferred into
tubes containing sodium citrate (0.129 mol/l; pH 7.4). Simulta-
neously we obtained blood samples from the cubital vein and
directly transferred them into sodium citrate medium. Collected
blood and synovial fluid samples were centrifuged at 8006g for
15 min, aliquoted and stored frozen at270uC until use. The study
was approved by the Ethics Committee of Sahlgrenska University
Hospital. All studies were conducted in compliance with the
Declaration of Helsinki, and all patients gave written informed
consent to participate in the study.
Flt3-L levels were determined by a sandwich ELISA using a pair
of matched antibodies (mouse and goat anti-human Flt3-L; R&D
Systems Abingdon, United Kingdom). Briefly, 96-well polystyrene
dishes (Nunc, Roskilde, Denmark) were coated with mouse anti-
human Flt3-L capture antibodies and incubated over night at 5uC.
Following washes with PBS containing 0.05%Tween 20, plates were
blocked with 1% bovine serum albumin (BSA, Sigma, St Louis, MO)
for one hour. Samples were diluted 1:10 in PBS containing 1% BSA.
Biotinylated goat anti-human Flt3-L detection antibodies were used
and streptavidin-HRP with corresponding substrate and chromogen
were employed for colour development. Double wavelength
registration at 450 and 540 nm was used and the difference of
absorbances was calculated. The obtained absorbance values were
compared with the serial dilutions of recombinant human Flt3-L and
are presented as picograms per millilitre.
Intra-articular injections of Staphylococcus aureus
derived peptidoglycan and Flt3-L
We wanted to analyze whether the increased i.a. levels of Flt3-L
in RA patients might affect inflammatory responses in vivo. To
this end we injected the knee joints of twenty-seven healthy 6-
Table 1. Clinical data regarding 130 RA-patients and 103 controls participating in the study.
RA-patients,
females (n=90)
RA-patients,
males (n =40)
Control subjects,
serum (n=70)
Control subjects,
synovial fluid (n =37)
Mean age (SD) 61(17) 59(13) 52(11) 47(21)
Disease duration, years (range) 10 (0–41) 9 (0–39) – –
White blood cells, mean (SD) 8.2(2.6) 7.9(2.2) N.A. * N.A.
RF positive 51 (57%) 27 (68%) N.A. N.A.
Erosive disease 51 (57%) 27 (57%) N.A. N.A.
DMARD-treatment 51 (57%) 24 (60%) None None
Methotrexate (Mtx) alone 25 12
Mtx and/or other DMARD 15 8
Mtx and TNFa-/IL-1-inhibitor 10 4
Other DMARDs and TNFa-inhibitor 1 0
No DMARD- treatment 39 16
*N.A. = not analyzed.
doi:10.1371/journal.pone.0003633.t001
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weeks old female NMRI-mice (B&K Universal AB, Stockholm,
Sweden) with Staphylococcus aureus derived peptidoglycan (Pep),
10 ng/knee, to induce arthritis. Pep has been shown to induce
arthritis when injected intraarticularly into murine knee joints in
the amount of 20–100 mg/joint [10]. In thirteen of these mice we
also injected 2 ng/knee of recombinant mouse Flt3-L (R&D
Systems) together with the peptidoglycan. In control experiments
recombinant mouse Flt3-L (R&D Systems) was injected i.a. in the
knee joints of healthy 6-weeks old female NMRI-mice at 0.02 ng/
joint (n = 5), 0.2 ng/joint (n = 5), and 2 ng/joint (n = 5).
All mice were killed after three days and the knee joints were
decalcified in 10% formic acid for 24 hours prior to fixation and
paraffin embedding. Serial sections were cut through the whole
knee joint and stained with hematoxylin and eosin. Arthritis was
evaluated on the scale ranging 0–3 where 0 is normal and 3 severe
arthritis. Signs of cartilage and bone erosivity were evaluated
separately. All animal experiments were approved by the Ethics
Committee of Go¨teborg University.
Intra-articular transfer of Flt3-L secreting cells
The mouse hybridoma cell line Sp2.0 transfected with gene for
soluble Flt3-L and identical non transfected clone were grown in
Dulbecco’s modified Eagle’s medium (4 mML-glutamine adjusted to
contain 1.5 g/L sodium bicarbonate and 4,5 g/L glucose, 90%; 10%
fetal bovine serum and Gentamycin). They were cultured at 37uC,
5% CO2 and passaged twice a week. Immediately prior to injection
the cells were centrifuged at 1000 RPM for fiveminutes and the pellet
was resuspended and diluted to proper concentration in sterile PBS.
To ensure that the myeloma cell line was producing Flt3-L,
levels of Flt3-L in the cell culture supernatants were determined by
a sandwich ELISA using a pair of matched antibodies (R&D
Systems). Flt3-L gene transfected cells showed high amount of
Flt3-L in supernatant while control myeloma cells did not produce
any (data not shown).
In preliminary experiments we injected healthy 6-weeks old
female Balb/C mice (B&K Universal AB, Stockholm, Sweden) i.a.
in knee joint or intra-peritoneally with the Balb/C derived
myeloma cell line transfected with the gene for mouse Flt3-L (Bc/
Flt3l+) or with identical cells (Bc/Flt3l-) from the same cell line as a
control, respectively. Twelve mice were injected i.p. with 16107
cells of the myeloma cell line. Six of the mice received the Bc/
Flt3l+ cells and six mice received the (Bc/Flt3l-) cells. Half of the
mice were killed after three days and the other half after seven
days. Intra-peritoneal lavage was performed on all mice with cell
counts of the peritoneal fluid. Knee joints were prepared for
histological examination.
Next, fifty-eight healthy 6-weeks old female Balb/C mice were
injected i.a. in the knee joint with the cell line. The right joint
received the (Bc/Flt3l+) and the left joint the (Bc/Flt3l-) cells. The
cell numbers were the following: 16106 cells n = 6, three mice
killed after 3 days and three after 7 days; 16105 cells n = 6, three
mice killed after 3 days and three after 7 days; 16104 n= 36,
thirteen mice killed after 3 days, thirteen after 7 days and ten after
30 days; 16103 cells n = 10, five mice killed after 3 days and five
mice after 7 days. After the mice were killed the knee joints were
decalcified, fixed and paraffin embedded. Serial sections were cut
through the whole knee joint and were stained with hematoxylin
and eosin. Degree of arthritis was scored as described above. All
animal experiments were approved by the Ethics Committee of
Go¨teborg University.
Statistical evaluation
The Flt3-L levels in serum and synovial fluid from RA-patients
and controls were compared using the Mann-Whitney U-test. We
stratified the patient material according to gender, presence of RF,
radiological findings (erosive vs non-erosive RA) and calculated the
difference regarding Flt3-L levels between the groups using the
Mann-Whitney U-test. The relationship between the Flt3-L levels
of the RA-patients and duration of disease, age, white blood cell
count in serum and synovial fluid, CRP and ESR was calculated
employing the Spearman correlation coefficient. The RA-patients
were further divided into two cohorts of age, a young (,53 years)
and an old (.53 years), and the levels of Flt3-L were compared
using the Mann-Whitney U-test.
Figure 1. Flt3-L levels in synovial fluids and sera of RA patients and of control subjects. Median displayed in the horizontal line. RA serum
(n = 130, median 80, range (min 0–max 3320), RA SF (n = 130, median 160 pg/ml, range (min 20–max 1980), control subjects serum (n= 70, median
70.5 pg/ml, range (min 0–max 160), and control subjects SF (n = 37, median 120 pg/ml, range (min 0–max 360).
doi:10.1371/journal.pone.0003633.g001
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x-square-test was performed to evaluate differences on the
frequency of arthritis in the mice that received Flt3-L and/or Pep
and the mice that received the cell line overexpressing Flt3-L. For
the statistical evaluation of the results, p,0.05 was considered
significant.
Results
Flt3-L levels in synovial fluids and sera of RA patients
We found significantly higher levels of Flt3-L in the synovial
fluid (mean 218 pg/ml, SEM 19) as compared to serum levels
(mean 141 pg/ml, SEM 35) in RA patients (p = 0.0001) (Fig. 1). In
addition, RA synovial fluid levels of Flt-3-L were significantly
higher than these obtained from synovial fluids originating from
non-inflammatory joint diseases (mean 132 pg/ml, SEM 12)
(p = 0.022). There was no significant difference in the circulating
Flt3-L levels between patients and controls (mean 74 pg/ml, SEM
4). Interestingly, controls with degenerative/traumatic joint
diseases also showed significantly elevated levels of Flt3-L in SF
compared to serum (p= 0.0001). Further statistical analysis
showed that Flt3-L had a positive correlation to age, both
regarding serum and synovial fluid levels. This was not seen in the
controls. The RF+ patients displayed significantly increased
(p,0.0001) levels of Flt3-L in serum but not in SF compared to
RF- patients. The older cohort of RA-patients (.53 years, n = 97)
had significantly higher levels of Flt3-L both in serum (p= 0.0155)
and SF (p = 0.0232) compared to the younger cohort (,53 years,
n = 33).
Intra-articular co-injection of Staphylococcus aureus
derived peptidoglycan and Flt3-L leads to aggravation of
arthritis
The histological findings of arthritis in the Pep-injected NMRI-
mice were of moderate severity. Microscopic examination of the
knee joints showed significantly higher (p,0.05) frequency of
arthritis of the mice co-injected with Pep and Flt3-L. Indeed 12 of
13 (92%) mice showed signs of mild to moderate arthritis compared
to 8 of 14 (57%) in the group that only received Pep. These data
indicate that Flt3-L potentiates peptidoglycan triggered joint
inflammation. Notably, a single i.a. injection of Flt3-L (0.02 ng,
0.2 ng, 2 ng/joint) did noy cause joint inflammation.
Intraarticular transfer of cells overexpressing Flt3-L leads
to destructive arthritis
Balb/C mice that received i.a. 16104 Balb/C derived B cell
clone transfected with the gene for murine Flt3-L developed after
three days histopathological signs of arthritis. Indeed, there was a
significantly higher frequency of arthritis since 8/13 (62%) mice
developed joint inflammation compared to 3/13 (23%) (p,0.05).
After seven days most of the arthritic process has disappeared since
only 2/13 mice in each group showed signs of arthritis. The mice
that were killed thirty days following injection showed no
difference between the groups in frequency of arthritis but there
were signs of bone erosions only in the joints that received Flt3-L
expressing cells. Five out of ten of the knee joints injected with
Flt3-L-expressing cells showed severe signs of arthritis, and all
these joints also showed great tumour masses intra- and
extraarticularly. Three out of five joints in this group also showed
severe destruction of bone (Figure 2). In the control group 4/10
showed signs of arthritis but great tumor masses were only seen in
one of the controls and no signs of bone erosions were visible.
There were no signs of arthritis when the number of hybridoma
cells exceeded 16105/knee or if the cells were provided i.p. Fi
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Discussion
Our results show that continuous exposure in vivo to Flt3-L
induces arthritis in healthy mice. Further, long term exposure to
Flt3-L gives rise to significant articular erosivity. We also show that
addition of Flt3-L worsens peptidoglycan-induced arthritis in
mouse and finally that the levels of Flt3-L are significantly elevated
in the synovial fluid of patients with RA.
Flt3-L and its receptor have never been studied in the setting of
autoimmune diseases in general or experimental arthritis in
particular. We have demonstrated that Flt3-L is strongly expressed
at the site of inflammation in human RA. In our material, two
known prognostically negative outcome variables for RA, RF+ and
high age, correlated to high levels of Flt3-L. Having in mind the
arthritogenic properties of Flt3-L, this supports the hypothesis of
Flt3-L having a role in induction and/or progression of arthritis.
However, in our clinical material we found no correlation to erosive
disease. One possible explanation to this is the patient material
displaying long disease duration and a large majority of the patients
exhibiting established arthritis. In these patients the erosive course of
disease has taken place long time ago and the current levels of Flt3-L
reflected merely maintenance of arthritis rather than its induction.
This calls for further studies of patients with an early disease onset.
Indeed, our preliminary data support the notion that in early RA
levels of Flt3-L display significant correlation to the erosive course of
the disease (Dehlin et al, unpublished).
Three possible mechanisms of action for Flt3-L may contribute
to the development of arthritis. Flt3L could increase antigen
presentation through increased differentiation of macrophages and
dendritic cells, both in the joint but also extra-articularly with
dendritic cells migrating to lymph nodes. A second mode of action
would be expansion and differentiation of B- and T-cells. This
would mainly take place extra-articularly since Flt3-L increases
progenitor cells in peripheral blood but these could migrate into
the joint. The third, and the most likely explanation, would be
Flt3-ligand-mediated activation of synovial dendritic cells, macro-
phages and fibroblasts giving rise to production of pro-inflamma-
tory cytokines which might initiate joint inflammation even in the
absence of T- and B-cells.
The prognosis of RA has lately greatly improved owing to better
pharmacologic treatment but this has generated a need for better
predictive markers in general and for erosive disease in particular.
Our experimental results indicate that Flt3-L could be involved in
the erosive process during joint inflammation. Joint destruction is
mainly mediated by macrophages and fibroblasts that invade
cartilage and activated osteoclasts which in turn cause bone
resorption. Osteoclasts are derived from mononuclear phagocyte
precursors in the presence of RANKL and macrophage colony-
stimulating factor (M-CSF). A recent study has shown that Flt3-L
can substitute M-CSF in support of osteoclast differentiation and
function [11]. Flt3-L has also been shown to mobilize osteoclasto-
genic progenitors in non-human primates in vivo [12]. Thus, the
elevated levels of Flt3-L in the synovial fluid might indeed
stimulate osteoclast differentiation and thereby become a mediator
of erosive disease.
In this study we provide support for Flt3-L concerning both
development of and erosive course of arthritis. These data will be
further validated in a large prospective RA study presently being
evaluated.
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